Abstract
Background Mepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care.
Objective To investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that there are characteristics that distinguish which patients would remain on mepolizumab and which patients would discontinue the medication.
Methods Between 2016 and 2022, patients who started on mepolizumab consented to be assessed over 18 months. At baseline, a questionnaire including demographic and medical history was collected. Laboratory findings such as ACT score, FENO (Fractional Excretion of Nitric Oxide), and spirometry were recorded. At the conclusion of the observation period, the participants were divided into two categories: Group A and Group B.
Results Group B [N=28] discontinued mepolizumab (P < 0.05) at an average of 5.8 months (SD 4.2 months). Group A [N=129] stayed on the therapy for at least 1 year. A participant with an ACT score less than 13 has an odds ratio of 6.64 (95% CI, 2.1 – 26.0) of discontinuing mepolizumab therapy. For a male, the odds of discontinuing mepolizumab therapy is 3.39 (95% CI, 1.1 – 11.2).
Conclusion In this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.
Competing Interest Statement
All authors declare that they have received no support from any organization for the submitted work; MA does consultancy for Sanofi, EP did consultancy for AstraZeneca over two years ago; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
The study was supported by the National Heart, Lung, and Blood Institute (HL103453 and HL081064). NS was supported by the Cleveland Clinic Catalyst Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB #8351 of Cleveland Clinic gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The title needed to be grammatically fixed.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- ACT
- asthma control test
- AUC
- area under curve
- BMI
- body mass index
- CAD
- coronary artery disease
- CBC
- complete blood count
- CHF
- congestive heart failure
- DBP
- diastolic blood pressure
- FDA
- Federal Drug Administration
- FENO
- fractional excretion of nitric oxide
- FEV1
- forced expiratory volume in one second
- GERD
- gastroesophageal reflux disease
- GINA
- Global Initiative for Asthma
- GSK
- GlaxoSmithKline
- ICS
- inhaled corticosteroids
- IQR
- interquartile range
- IRB
- Institutional Review Board
- LABA
- Long-acting beta agonist
- μL
- microliters
- ROC
- receiver operating curve
- SBP
- systolic blood pressure
- WBC
- white blood cell
